These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 9605412)

  • 1. PNU 157706, a novel dual type I and II 5alpha-reductase inhibitor.
    di Salle E; Giudici D; Radice A; Zaccheo T; Ornati G; Nesi M; Panzeri A; Délos S; Martin PM
    J Steroid Biochem Mol Biol; 1998 Feb; 64(3-4):179-86. PubMed ID: 9605412
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FCE 28260, a new 5 alpha-reductase inhibitor: in vitro and in vivo effects.
    Giudici D; Briatico G; Cominato C; Zaccheo T; Iehlè C; Nesi M; Panzeri A; di Salle E
    J Steroid Biochem Mol Biol; 1996 Jun; 58(3):299-305. PubMed ID: 8836165
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of the dual 5alpha-reductase inhibitor PNU 157706 on the growth of dunning R3327 prostatic carcinoma in the rat.
    Zaccheo T; Giudici D; di Salle E
    J Steroid Biochem Mol Biol; 1998 Feb; 64(3-4):193-8. PubMed ID: 9605414
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CGP 53153: a new potent inhibitor of 5alpha-reductase.
    Häusler A; Allegrini PR; Biollaz M; Batzl C; Scheidegger E; Bhatnagar AS
    J Steroid Biochem Mol Biol; 1996 Feb; 57(3-4):187-95. PubMed ID: 8645628
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of 5alpha-reductase in rat prostate reveals differential regulation of androgen-response gene expression by testosterone and dihydrotestosterone.
    Dadras SS; Cai X; Abasolo I; Wang Z
    Gene Expr; 2001; 9(4-5):183-94. PubMed ID: 11444528
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined treatment with the 5 alpha-reductase inhibitor PNU 157706 and the antiandrogen flutamide on the Dunning R3327 prostatic carcinoma in rats.
    Zaccheo T; Giudici D; di Salle E
    Endocr Relat Cancer; 1999 Sep; 6(3):429-35. PubMed ID: 10516856
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined treatment of Dunning R3327 rat prostatic tumor with the 5alpha-reductase inhibitor PNU 157706 and the antiandrogen bicalutamide.
    Zaccheo T; Giudici D; Panzeri A; di Salle E
    Cancer Chemother Pharmacol; 2000; 45(1):31-7. PubMed ID: 10647498
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 5alpha-reductase activity in the prostate.
    Steers WD
    Urology; 2001 Dec; 58(6 Suppl 1):17-24; discussion 24. PubMed ID: 11750244
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hormonal effects of turosteride, a 5 alpha-reductase inhibitor, in the rat.
    di Salle E; Giudici D; Briatico G; Ornati G; Panzeri A
    J Steroid Biochem Mol Biol; 1993 Nov; 46(5):549-55. PubMed ID: 8240976
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia.
    Bartsch G; Rittmaster RS; Klocker H
    Eur Urol; 2000 Apr; 37(4):367-80. PubMed ID: 10765065
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostate cancer cells differ in testosterone accumulation, dihydrotestosterone conversion, and androgen receptor signaling response to steroid 5α-reductase inhibitors.
    Wu Y; Godoy A; Azzouni F; Wilton JH; Ip C; Mohler JL
    Prostate; 2013 Sep; 73(13):1470-82. PubMed ID: 23813697
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of some novel inhibitors of C17,20-lyase and 5alpha-reductase in vitro and in vivo and their potential role in the treatment of prostate cancer.
    Nnane IP; Kato K; Liu Y; Lu Q; Wang X; Ling YZ; Brodie A
    Cancer Res; 1998 Sep; 58(17):3826-32. PubMed ID: 9731491
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of 5 alpha-reductase inhibitors on intraprostatic androgens in the rat.
    di Salle E; Giudici D; Biagini L; Cominato C; Briatico G; Panzeri A
    J Steroid Biochem Mol Biol; 1995 Jun; 53(1-6):381-5. PubMed ID: 7626485
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Androgen-induced prostate-specific antigen gene expression is mediated via dihydrotestosterone in LNCaP cells.
    Zhu YS; Cai LQ; You X; Cordero JJ; Huang Y; Imperato-McGinley J
    J Androl; 2003; 24(5):681-7. PubMed ID: 12954658
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Morphological and hormonal changes in the ventral and dorsolateral prostatic lobes of rats treated with finasteride, a 5-alpha reductase inhibitor.
    Prahalada S; Rhodes L; Grossman SJ; Heggan D; Keenan KP; Cukierski MA; Hoe CM; Berman C; van Zwieten MJ
    Prostate; 1998 May; 35(3):157-64. PubMed ID: 9582084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selectivity of finasteride as an in vivo inhibitor of 5alpha-reductase isozyme enzymatic activity in the human prostate.
    Span PN; Völler MC; Smals AG; Sweep FG; Schalken JA; Feneley MR; Kirby RS
    J Urol; 1999 Jan; 161(1):332-7. PubMed ID: 10037433
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of steroid 5alpha-reductase inhibitor ONO-9302 and anti-androgen allylestrenol on the prostatic growth, and plasma and prostatic hormone levels in rats.
    Yasuda N; Fujino K; Shiraji T; Nambu F; Kondo K
    Jpn J Pharmacol; 1997 Jul; 74(3):243-52. PubMed ID: 9268084
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A multiscale, mechanism-driven, dynamic model for the effects of 5α-reductase inhibition on prostate maintenance.
    Zager MG; Barton HA
    PLoS One; 2012; 7(9):e44359. PubMed ID: 22970204
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of finasteride (Proscar), a 5 alpha reductase inhibitor, and various commercial plant extracts in in vitro and in vivo 5 alpha reductase inhibition.
    Rhodes L; Primka RL; Berman C; Vergult G; Gabriel M; Pierre-Malice M; Gibelin B
    Prostate; 1993; 22(1):43-51. PubMed ID: 8381228
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the effects of the 5 alpha-reductase inhibitor finasteride and the antiandrogen flutamide on prostate and genital differentiation: dose-response studies.
    Imperato-McGinley J; Sanchez RS; Spencer JR; Yee B; Vaughan ED
    Endocrinology; 1992 Sep; 131(3):1149-56. PubMed ID: 1324152
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.